Wait for More Clarity Before Buying Gilead Stock, Says Analyst

Gilead Sciences (GILD) has outperformed the market in 2020, up nearly 16%, as hopes have been pinned on its ability to bring a viable COVID-19 treatment to market.The Phase 3 SIMPLE trial evaluating remdesivir as a 5 and 10-day treatment for moderately ill COVID-19 patients compared to placebo, found that by the primary end point of day 11, those given the medication for 5 days were more likely to show a clinical improvement than those receiving standard care. However, patients taking the medici